Danske Bank A S Has $196.36 Million Stock Holdings in Merck & Co., Inc. $MRK

Danske Bank A S decreased its stake in Merck & Co., Inc. (NYSE:MRK - Free Report) by 2.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,865,444 shares of the company's stock after selling 40,586 shares during the period. Danske Bank A S owned 0.08% of Merck & Co., Inc. worth $196,357,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Westside Investment Management Inc. increased its stake in shares of Merck & Co., Inc. by 3.1% in the fourth quarter. Westside Investment Management Inc. now owns 3,142 shares of the company's stock valued at $331,000 after buying an additional 93 shares during the period. Valued Wealth Advisors LLC boosted its position in shares of Merck & Co., Inc. by 26.9% during the 4th quarter. Valued Wealth Advisors LLC now owns 444 shares of the company's stock valued at $47,000 after purchasing an additional 94 shares in the last quarter. Payne Capital LLC boosted its position in shares of Merck & Co., Inc. by 0.9% during the 4th quarter. Payne Capital LLC now owns 10,637 shares of the company's stock valued at $1,120,000 after purchasing an additional 97 shares in the last quarter. Abound Wealth Management boosted its position in shares of Merck & Co., Inc. by 6.8% during the 4th quarter. Abound Wealth Management now owns 1,554 shares of the company's stock valued at $164,000 after purchasing an additional 99 shares in the last quarter. Finally, ST Germain D J Co. Inc. boosted its position in shares of Merck & Co., Inc. by 0.3% during the 4th quarter. ST Germain D J Co. Inc. now owns 38,645 shares of the company's stock valued at $4,068,000 after purchasing an additional 99 shares in the last quarter. Institutional investors and hedge funds own 76.07% of the company's stock.

Analyst Ratings Changes

Several equities research analysts recently commented on MRK shares. Zacks Research upgraded Merck & Co., Inc. from a "strong sell" rating to a "hold" rating in a research report on Tuesday, March 17th. Wolfe Research upgraded Merck & Co., Inc. from a "peer perform" rating to an "outperform" rating and set a $135.00 target price on the stock in a research report on Thursday, January 8th. Deutsche Bank Aktiengesellschaft upgraded Merck & Co., Inc. from a "hold" rating to a "buy" rating and set a $150.00 target price on the stock in a research report on Friday, February 13th. Royal Bank Of Canada restated an "outperform" rating and set a $142.00 target price on shares of Merck & Co., Inc. in a research report on Monday, March 30th. Finally, JPMorgan Chase & Co. upped their target price on Merck & Co., Inc. from $125.00 to $135.00 and gave the company an "overweight" rating in a research report on Monday, April 6th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat.com, Merck & Co., Inc. presently has a consensus rating of "Moderate Buy" and a consensus target price of $128.47.

Insiders Place Their Bets

In other news, EVP Richard R. Deluca sold 37,685 shares of the stock in a transaction that occurred on Friday, February 6th. The stock was sold at an average price of $120.92, for a total value of $4,556,870.20. Following the completion of the sale, the executive vice president directly owned 160,174 shares of the company's stock, valued at $19,368,240.08. This represents a 19.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Caroline Litchfield sold 41,997 shares of the stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $119.61, for a total value of $5,023,261.17. Following the completion of the sale, the chief financial officer directly owned 90,192 shares of the company's stock, valued at approximately $10,787,865.12. This trade represents a 31.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 320,176 shares of company stock valued at $38,281,735. 0.17% of the stock is currently owned by corporate insiders.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Q1 results and product momentum: Merck beat Q1 revenue and adjusted EPS expectations, driven by continued Keytruda demand and contributions from newer launches (Winrevair reported at ~$525M), which underpin near‑term revenue growth. Merck Sales Beat As Winrevair Hits $525 Million
• Positive Sentiment: Management raised adjusted EPS guidance and emphasized oncology strength: Merck narrowed its 2026 guidance range but lifted its profit outlook on stronger Keytruda and new product trends, a positive for earnings power even as revenue bands were tightened. Merck beats quarterly estimates on strength of Keytruda and new products, narrows outlook
• Positive Sentiment: Clinical pipeline progress: Merck dosed the first patient in Phase 3 studies of enpatoran for lupus skin manifestations — a near‑term clinical milestone that could add long‑term pipeline value if successful. Merck Announces First Dose in Phase 3 Study with Enpatoran
• Neutral Sentiment: Calls and disclosures available: The full Q1 earnings call transcript and the investor slide deck are posted for deeper review of sales mix, margin drivers and forward guidance assumptions. Q1 2026 Earnings Call Transcript Earnings Presentation
• Neutral Sentiment: Minor analyst estimate moves: Some shops trimmed FY forecasts modestly (e.g., Erste’s slight EPS tweak), indicating traders are tweaking models but not overhauling consensus. MRK Q1 Earnings & Sales Beat; 2026 Sales View Tightened
• Negative Sentiment: One‑time acquisition charge produced a GAAP loss: Merck reported a quarterly loss driven by a Cidara‑related acquisition charge, which suppresses headline earnings and can weigh on near‑term sentiment. Merck posts quarterly loss due to Cidara charge
• Negative Sentiment: Tighter revenue guidance and mixed product trends: Management narrowed the sales range for 2026 and flagged mixed growth among some newer and legacy products, which leaves upside constrained and raises uncertainty about sustained top‑line acceleration. Merck Q1 earnings beat; 2026 guidance narrowed
• Negative Sentiment: Market concerns about future sales erosion: Commentary and coverage highlighted risks from expected declines in certain legacy drugs (HPV vaccine, diabetes medicine) and the company’s efforts to offset those losses, which contributes to investor caution. Merck Stock Falls After Earnings

Merck & Co., Inc. Stock Down 1.5%

Shares of NYSE:MRK opened at $109.33 on Friday. The business's 50 day simple moving average is $117.69 and its two-hundred day simple moving average is $107.39. The firm has a market cap of $270.03 billion, a P/E ratio of 15.02, a PEG ratio of 2.25 and a beta of 0.26. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.30 and a current ratio of 1.54. Merck & Co., Inc. has a 52-week low of $73.31 and a 52-week high of $125.14.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.47) by $0.19. The business had revenue of $16.29 billion for the quarter, compared to analyst estimates of $15.85 billion. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The company's quarterly revenue was up 4.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.22 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, research analysts forecast that Merck & Co., Inc. will post 4.89 EPS for the current fiscal year.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.